The Cyclin A2 gene (CCNA2), which turns off after birth in humans, can promote cardiac repair in adult human cardiomyocytes.

NurExone’s U.S. subsidiary, Exo-Top Inc., is advancing plans for the establishment of a GMP-compliant facility dedicated to naive exosome production. The Company believes participation in ARMI’s ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team ...

The site will feature smart microgrids, solar, and advanced battery storage – a step toward sustainable industrial infrastructure in Florida.

The human heart has the ability to repair itself, scientists have found, in a breakthrough that could provide a lifeline for hundreds of thousands of patients.

Alkem Foundation and IIT Bombay have partnered to establish a research center for immuno-therapeutics and regenerative medicine. The center aims to foster innovation, fill research gaps, and ...

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...

Artificial Intelligence, or AI, is now transforming how we detect, prevent and treat illness, promising earlier interventions, smarter therapies and more affordable care for everyone.​ ...

Pres. Herzog and top health CEOs will headline a summit on embedding AI in decision-making and breakthrough stem cell research at Reichman University.

Explore how Tabasheer and Bu Zhong Yi Qi Tang restore fascia integrity and Qi balance in connective tissue healing through an ...

Serves pharmaceutical companies, healthcare providers, and research organizations seeking advanced therapeutics and ...